NGL Fine Chem Ltd
Pharmaceuticals & Biotechnology | Small Cap
NGL Fine Chem Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Growth metrics are generally positive, driven by revenue, EPS, asset, and net income growth. However, operating profit growth lags. The company's coverage ratios are robust, reflecting a good ability to meet its obligations. Liquidity is adequate, although cash and operating cash flow ratios are weak. Efficiency ratios present challenges, particularly in fixed asset and capital turnover. Financial metrics are average, with book value as a relative strength but dividends and capital expenditures need attention. Despite some weaknesses, NGL Fine Chem's strategic positioning in the Healthcare Services sector supports a positive outlook, contingent on addressing operational inefficiencies and sustaining growth momentum.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.80
- Financial Ratio4.60
- Profitability Ratio10.00
- Efficiency Ratio4.00
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio5.04
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayStrong Bullish
- 1 WeekBullish
- 1 MonthBullish
NGL Fine Chem Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Growth metrics are generally positive, driven by revenue, EPS, asset, and net income growth. However, operating profit growth lags. The company's coverage ratios are robust, reflecting a good ability to meet its obligations. Liquidity is adequate, although cash and operating cash flow ratios are weak. Efficiency ratios present challenges, particularly in fixed asset and capital turnover. Financial metrics are average, with book value as a relative strength but dividends and capital expenditures need attention. Despite some weaknesses, NGL Fine Chem's strategic positioning in the Healthcare Services sector supports a positive outlook, contingent on addressing operational inefficiencies and sustaining growth momentum.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
45.19
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
39.09
P/B RATIO
5.71
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
3.46
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
-11.56
EV/EBITDA RATIO
20.54
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹3045.4 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤3rd Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Concall Report⬤18th Nov 25
Q2 and H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
The company demonstrates strong growth in revenue, EPS, assets, and net income, indicating a positive trajectory. However, the decline in operating profit growth is a concern. The company's ability to sustain overall growth depends on improving operational efficiency and profitability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 23.26 | -12.58 | 21.94 | 8.55 | 36.14 |
| Operating Profit Growth Rate | -15 | -48.53 | 54.29 | -35.19 | 108.57 |
| Earnings Per Share (EPS) Growth | -12.02 | -58.92 | 101.57 | -48.88 | 127.87 |
| Asset Growth Rate | 33.82 | 3.61 | 24.04 | 21.63 | 26.1 |
| Net Income Growth Rate | -12.28 | -60 | 105 | -48.78 | 128.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed picture. While book value per share is a relative strength, adjusted and cash EPS are average. Low dividend per share and high capital expenditures suggest a focus on reinvesting earnings rather than distributing them to shareholders. The company should balance reinvestment with shareholder returns.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 83.33 | 33.33 | 68.33 | 35 | 80 |
| Cash Earnings Per Share (Cash EPS) | 100 | 51.67 | 88.33 | 55 | 113.33 |
| Book Value Per Share | 338.33 | 370 | 438.33 | 470 | 548.33 |
| Dividend Per Share (DPS) | 1.62 | 1.66 | 2.01 | 1.71 | 0 |
| Capital Expenditures (CapEx) | 29 | 30 | 29 | 74 | 86 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits excellent profitability ratios, indicating strong financial performance. High gross profit, ROCE, ROE, ROA, operating margin, and net margin all reflect efficient operations and effective management. The company's ability to generate profits is a positive sign.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.24 | 8.63 | 12.39 | 6.25 | 10.58 |
| Return on Capital Employed (ROCE) | 34 | 12 | 20 | 9 | 17 |
| Return on Equity (ROE) | 24.63 | 9.01 | 15.59 | 7.45 | 14.59 |
| Return on Assets (ROA) | 24.55 | 12.2 | 15.17 | 8.08 | 13.37 |
| Operating Margin | 21.38 | 12.59 | 15.93 | 9.51 | 14.57 |
| Net Margin | 15.72 | 7.19 | 12.09 | 5.71 | 9.58 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios show mixed performance. While the inventory turnover is average, fixed asset and capital turnover are low, suggesting inefficient asset utilization. The receivable days are high, indicating slow collection of payments. There is room to improve asset management and streamline operations to enhance efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.57 | 3.16 | 3.94 | 2.57 | 3.05 |
| Inventory Turnover Ratio | 5.51 | 6.12 | 8.49 | 7.34 | 7.4 |
| Receivables Turnover Ratio | 6.24 | 4.28 | 4.35 | 4.28 | 4.7 |
| Days Sales in Inventory Ratio | 66.24 | 59.64 | 42.99 | 49.73 | 49.32 |
| Receivable Days | 58.49 | 85.28 | 83.91 | 85.28 | 77.66 |
| Capital Turnover Ratio | 1.52 | 1.23 | 1.27 | 1.18 | 1.3 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company demonstrates excellent coverage ratios, indicating a strong ability to meet its interest and dividend obligations. This reflects financial stability and prudent financial management. The company's ability to meet its interest and dividend obligations show its financial strength.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 34.5 | 14.5 | 28 | 10.33 | 16.75 |
| Equity Dividend Coverage Ratio | 50 | 20 | 33.33 | 20 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, indicating a robust financial structure. Low debt and high equity ratios suggest a conservative approach to financing. A low debt-to-asset ratio further confirms the company's financial stability. The company's reliance on equity rather than debt is a positive sign.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.03 | 0.02 | 0.01 | 0.09 | 0.15 |
| Debt to Equity Ratio | 0.03 | 0.02 | 0.01 | 0.1 | 0.18 |
| Equity Ratio | 0.97 | 0.98 | 0.99 | 0.91 | 0.85 |
| Debt To Asset Ratio | 0.02 | 0.01 | 0.01 | 0.07 | 0.1 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position shows a mix of strengths and weaknesses. A good quick ratio indicates the ability to meet short-term obligations with its most liquid assets. However, low cash and operating cash flow ratios suggest the company might face challenges in meeting immediate cash needs. While the current ratio is average, there is room to optimize cash management and improve overall liquidity.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.28 | 2.22 | 1.88 | 1.48 | 1.54 |
| Quick Ratio | 1.45 | 1.77 | 1.41 | 1.07 | 1.11 |
| Cash Ratio | 0.01 | 0.22 | 0.02 | 0.05 | 0.03 |
| Operating Cash Flow Ratio | 0.21 | 0.58 | 0.22 | 0.3 | 0.27 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.87 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | NGL Fine Chem Ltd | 6.98 | 39.09 | Overvalued | 73.00 | 67.39 | 48.00 |
| 4 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 5 | Kilitch Drugs (India) Ltd | 6.61 | 21.17 | Neutral | 37.00 | 9.27 | 30.00 |
| 6 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 7 | SMS Lifesciences India Ltd | 6.59 | 21.78 | Neutral | 45.00 | 70.68 | 19.00 |
| 8 | Infinium Pharmachem Ltd | 6.42 | 26.49 | Neutral | 22.00 | 6.43 | 14.00 |
| 9 | Sakar Healthcare Ltd | 5.81 | 58.09 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 31.76 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -272.76 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 26.36 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 35.36 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 28.05 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
NGL Fine Chem's management effectiveness is mixed due to declining profit growth and increased borrowings, despite positive sales growth. The company shows moderate capital efficiency, but declining operating profit margins are concerning. Strong promoter holding provides some stability. Overall, management faces challenges in sustaining growth and managing profitability.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (5Y) | 19% | Strong Revenue Expansion |
| Promoter Holding | 72.74% | High Promoter Confidence | |
| CONS | Profit Growth (3Y) | -25% | Declining Profitability |
| Operating Profit Margin (TTM) | 9% | Reduced Operational Efficiency |
Financial Performance & Growth
NGL Fine Chem's financial performance shows positive sales growth but a concerning decline in profit growth. The company's recent quarterly results show fluctuating sales and profit growth, with a significant drop in YOY Profit Growth in the most recent quarter.
| Metric | 2019-2021 | 2022-2024 | 2025 |
|---|---|---|---|
| Sales Growth (%) | 30.72% | 6.46% | 8.73% |
| Profit Growth (%) | - | -8.75% | -58.54% |
Capital Efficiency & Returns
The company's ROCE has fluctuated, showing a decline in the most recent year. ROE also indicates a decreasing trend, suggesting that the company's ability to generate returns from its capital and equity has weakened recently.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 14% | 54% | 34% | 12% | 20% | 9% |
| ROE (%) | - | - | - | - | - | 8% |
Financial Health & Prudence
NGL Fine Chem's financial health shows concerning trends with increased borrowings. The Debt/Equity ratio has increased, indicating higher financial leverage.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Borrowings | 27 | 28 | 16 | 30 | 32 | 34 | 73 |
Shareholding & Ownership Structure
The shareholding pattern reveals a strong promoter holding. However, there has been a slight decrease in promoter holding over the years.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Promoter Holding (%) | 73.81% | 73.81% | 73.81% | 73.53% | 72.74% | 72.74% |
NGL Fine Chem presents a moderate risk profile due to declining profit growth and increasing debt. While sales have grown, profitability metrics have deteriorated. Promoter holding remains strong, providing some stability. The company's financial performance needs monitoring to mitigate potential risks.
Segment performance volatility
There is no specific data available on segment performance volatility.
Foreign exchange or interest rate exposure
There is no specific data available on foreign exchange or interest rate exposure.
Regulatory compliance cost trends
There is no specific data available on regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 103074.17Bullish
- SMA 203021.22Bullish
- SMA 502976.72Bullish
- EMA 103064.76Bullish
- EMA 203040.06Bullish
- EMA 502977.15Bullish
- DEMA 103090.50Bearish
- DEMA 203081.18Bearish
- DEMA 503077.26Bullish
- TEMA 103091.43Bearish
- TEMA 203086.05Bearish
- TEMA 503084.58Bearish
- MACD31.82Bullish
- ADX18.79Weak Trend
- IndicatorValueSignal
- RSI57.11Neutral
- CCI56.41Neutral
- ROC 91.91Bullish
- ROC 144.05Bullish
- ROC 253.60Bullish
- Stoch K72.14Neutral
- Stoch D74.05Neutral
- IndicatorValueSignal
- BB Upper3151.39Neutral
- BB Middle3021.22Neutral
- BB Lower2891.05Neutral
- ATR68.76Low Volatility
- IndicatorValueSignal
- MFI59.98Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 103027.85Bullish
- SMA 203027.84Bullish
- SMA 502875.22Bullish
- EMA 103045.77Bullish
- EMA 203008.62Bullish
- EMA 502904.10Bullish
- DEMA 103080.84Bearish
- DEMA 203079.20Bullish
- DEMA 503061.04Bullish
- TEMA 103086.48Bearish
- TEMA 203079.14Bullish
- TEMA 503083.35Bearish
- MACD51.74Bullish
- ADX11.31Weak Trend
- IndicatorValueSignal
- RSI58.92Neutral
- CCI39.11Neutral
- ROC 95.37Bullish
- ROC 144.16Bullish
- ROC 2512.53Bullish
- Stoch K73.44Neutral
- Stoch D74.91Neutral
- IndicatorValueSignal
- BB Upper3168.18Neutral
- BB Middle3027.84Neutral
- BB Lower2887.50Neutral
- ATR96.45Low Volatility
- IndicatorValueSignal
- MFI57.76Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 103041.07Bullish
- SMA 202939.49Bullish
- SMA 502740.95Bullish
- EMA 103021.33Bullish
- EMA 202949.78Bullish
- EMA 502774.71Bullish
- DEMA 103084.97Bearish
- DEMA 203081.71Bearish
- DEMA 503008.60Bullish
- TEMA 103079.42Bullish
- TEMA 203093.72Bearish
- TEMA 50N/AN/A
- MACD97.61Bullish
- ADX15.99Weak Trend
- IndicatorValueSignal
- RSI60.01Neutral
- CCI73.15Neutral
- ROC 9-0.42Bearish
- ROC 1410.00Bullish
- ROC 2514.50Bullish
- Stoch K75.40Neutral
- Stoch D70.92Neutral
- IndicatorValueSignal
- BB Upper3223.29Neutral
- BB Middle2939.49Neutral
- BB Lower2655.68Neutral
- ATR144.59Low Volatility
- IndicatorValueSignal
- MFI81.45Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102885.54Bullish
- SMA 202793.79Bullish
- SMA 502502.56Bullish
- SMA 1002314.11Bullish
- SMA 2001867.42Bullish
- EMA 102903.08Bullish
- EMA 202783.60Bullish
- EMA 502559.41Bullish
- EMA 1002314.38Bullish
- EMA 2002028.63Bullish
- DEMA 103026.73Bullish
- DEMA 202979.42Bullish
- DEMA 502847.21Bullish
- DEMA 1002720.82Bullish
- DEMA 2002393.43Bullish
- TEMA 103042.56Bullish
- TEMA 203033.15Bullish
- TEMA 502914.97Bullish
- TEMA 1002862.24Bullish
- TEMA 2002706.62Bullish
- MACD149.68Bullish
- ADX30.60Strong Trend
- IndicatorValueSignal
- RSI62.40Neutral
- CCI100.67Overbought
- ROC 149.35Bullish
- ROC 2539.88Bullish
- Stoch K66.79Neutral
- Stoch D71.80Neutral
- IndicatorValueSignal
- BB Upper3110.51Neutral
- BB Middle2793.79Neutral
- BB Lower2477.07Neutral
- ATR221.37High Volatility
- IndicatorValueSignal
- MFI70.38Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 202342.03Bullish
- SMA 501772.68Bullish
- EMA 202326.65Bullish
- EMA 501961.79Bullish
- DEMA 202714.49Bullish
- DEMA 502267.03Bullish
- TEMA 202842.92Bullish
- TEMA 502576.22Bullish
- MACD299.10Bullish
- ADX59.96Strong Trend
- IndicatorValueSignal
- RSI75.21Overbought
- CCI166.42Overbought
- ROC 1426.77Bullish
- ROC 25138.41Bullish
- Stoch K81.26Overbought
- Stoch D76.35Neutral
- IndicatorValueSignal
- BB Upper2912.29Overbought
- BB Middle2342.03Neutral
- BB Lower1771.77Neutral
- ATR340.14High Volatility
- IndicatorValueSignal
- MFI67.33Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 62073.57Bullish
- SMA 121710.88Bullish
- SMA 241724.76Bullish
- EMA 62169.11Bullish
- EMA 121911.33Bullish
- EMA 241769.52Bullish
- DEMA 62519.41Bullish
- DEMA 122171.67Bullish
- DEMA 241829.11Bullish
- TEMA 62669.06Bullish
- TEMA 122431.12Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX33.83Strong Trend
- IndicatorValueSignal
- RSI65.10Neutral
- CCIN/AN/A
- ROC 259.26Bullish
- ROC 50N/AN/A
- Stoch K35.75Neutral
- Stoch D29.62Neutral
- IndicatorValueSignal
- BB Upper2529.35Overbought
- BB Middle1610.71Neutral
- BB Lower692.07Neutral
- ATR461.50High Volatility
- IndicatorValueSignal
- MFI92.33Overbought